OncoSec Medical Inc (OQ:ONCS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 24 N Main St
PENNINGTON NJ 08534-2218
Tel: N/A
Website: oncosec.com
IR: See website
<
Key People
Margaret Dalesandro
Independent Chairman of the Board
Daniel J. O'Connor
President, Chief Executive Officer, Director
Robert J. DelAversano
Principal Accounting Officer, Controller
Business Overview
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company's lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).
Financial Overview
For the three months ended 31 October 2020, OncoSecMedical Inc revenues was not reported. Net loss increased35% to $13.2M. Higher net loss reflects Research anddevelopment - Balancing val increase of 65% to $8.8M(expense), Stock-based Compensation in R&D increase from$100K to $1M (expense), Stock-based Compensation in SGAincrease from $300K to $900K (expense).
Employees: 42 as of Jul 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $147.22M as of Oct 31, 2020
Annual revenue (TTM): $0.00M as of Oct 31, 2020
EBITDA (TTM): -$46.34M as of Oct 31, 2020
Net annual income (TTM): -$45.72M as of Oct 31, 2020
Free cash flow (TTM): -$34.75M as of Oct 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 27,991,274 as of Dec 11, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.